GeneDx Holdings (WGS) Gross Profit (2020 - 2026)

GeneDx Holdings (WGS) has reported Gross Profit for 7 consecutive years, with $68.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 16.65% year-over-year to $68.2 million; the TTM figure through Mar 2026 stood at $307.9 million (up 42.91% YoY), while the FY2025 annual figure was $298.2 million, up 53.38% from the prior year.
• Gross Profit declined to $68.2 million in Q1 2026 per WGS's latest filing, from $84.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $84.5 million in Q3 2025 and bottomed at -$29.6 million in Q2 2022.
• Historically, Gross Profit has averaged $36.7 million across 5 years, with a median of $37.4 million in 2024.
• Annual changes were most pronounced in 2022 — Gross Profit slumped 2442.78% — and 2023, when it soared 288.37%.
• GeneDx Holdings' Gross Profit stood at -$16.3 million in 2022, then jumped by 288.37% to $30.8 million in 2023, then surged by 115.27% to $66.2 million in 2024, then increased by 27.28% to $84.3 million in 2025, then slipped by 19.05% to $68.2 million in 2026.
• Business Quant data shows WGS's Gross Profit at $68.2 million in Q1 2026, $84.3 million in Q4 2025, and $84.5 million in Q3 2025.